NIH Highlighted Topic: Unexplained Anemia in Older Persons: Elucidating Etiologies, Improving Diagnoses, and Identifying and Testing Potential Treatment Strategies
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on improving understanding, diagnosis, and treatment of unexplained anemia of aging (UAA) — a major unmet clinical challenge affecting older adults. This highlighted topic supports multidisciplinary research aimed at uncovering the biological, clinical, and mechanistic causes of anemia in older individuals whose condition cannot currently be explained by existing diagnostic categories.
NIH estimates that approximately 30–50% of anemia cases in adults over age 65 remain unexplained, despite anemia being strongly associated with increased morbidity, mortality, reduced physical function, and diminished quality of life. The initiative is particularly interested in projects that improve identification of novel anemia subtypes, clarify disease mechanisms, develop precision diagnostics, and evaluate targeted therapeutic interventions.
Companies developing AI-enabled diagnostics, biomarker discovery platforms, hematology analytics systems, precision medicine technologies, geriatric care solutions, microbiome analytics, digital health monitoring systems, or novel therapeutic platforms may be strong candidates for funding.
Areas of interest include inflammatory and immune-related mechanisms, cellular senescence, clonal hematopoiesis, hormone-related pathways, microbiome interactions, multimorbidity modeling, cancer-related anemia risk, predictive analytics, clinical screening strategies, and intervention studies targeting newly identified anemia subtypes. NIH is also encouraging projects using novel alternative methods (NAMs), computational biology, translational models, and longitudinal epidemiologic studies to better understand aging-associated hematologic dysfunction.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported by the National Institute on Aging (NIA) and the National Cancer Institute (NCI), both of which are seeking transformative innovations that improve diagnosis, risk stratification, treatment outcomes, survivorship, and quality of life for older adults affected by unexplained anemia.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of diagnostics, biomarkers, predictive analytics systems, therapeutics, and translational research technologies related to unexplained anemia of aging (UAA).
Eligible activities may include:
AI and machine learning platforms for anemia subtype identification and risk prediction
Biomarker discovery and precision hematology diagnostic technologies
Computational biology and multimorbidity analytics systems
Microbiome and metabolomics research platforms related to aging-associated anemia
Inflammatory, immune, and cellular senescence pathway analysis technologies
Clonal hematopoiesis and genomic profiling systems
Wearable and remote monitoring technologies for geriatric health and anemia progression
Precision medicine and targeted therapeutic development platforms
Novel alternative methods (NAMs), organoid systems, and translational disease models
Longitudinal aging and epidemiological analytics infrastructure
Clinical screening, recruitment, and trial-matching technologies for older adults
Cancer survivorship and anemia-related treatment toxicity monitoring systems
Predictive analytics for therapy tolerance, recurrence, and mortality risk
Digital health and geriatric care coordination platforms
Hormone-related and metabolic pathway intervention technologies
Functional health and quality-of-life monitoring systems
Prototype development, translational studies, and clinical validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, software engineering, cloud infrastructure, AI model development, bioinformatics analysis, preclinical studies, clinical trial preparation, microbiome research, biomarker validation, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable hematology or aging-health solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
